Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Ryzneuta (efbemalenograstim alfa-vuxw) is a long-acting recombinant human granulocyte colony-stimulating factor (G-CSF) analog. It is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer chemotherapy associated with a clinically significant incidence of febrile neutropenia.
Ryzneuta is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
It is a prescription supportive-care medicine used alongside chemotherapy for cancer and must be administered under the supervision of a qualified oncologist.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Ryzneuta (efbemalenograstim alfa-vuxw) injection may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. The following documentation is required:
The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit.
Ryzneuta (efbemalenograstim alfa-vuxw injection) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Ryzneuta is not commercially marketed in India.
However, patients in India can legally access Ryzneuta through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of a specific patient for their personal treatment, under a valid prescription.
Ryzneuta is approved in the United States (US FDA, 2023), the European Union (EMA, 2024), and China (NMPA), ensuring full transparency throughout the process.
Ryzneuta can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) can source Ryzneuta from reliable global channels and facilitate supply to patients, doctors, and hospitals under applicable legal provisions. As a temperature-sensitive biologic, Ryzneuta requires cold-chain handling throughout transit and must be kept refrigerated between 2°C to 8°C, protected from light, and never frozen. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For Ryzneuta cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access Ryzneuta through regulated import pathways, with delivery arranged to the treating hospital based on a valid oncologist's prescription, alongside their chemotherapy regimen.
A major oncology hub with institutions like Tata Memorial, Mumbai coordinates supportive-care therapies like Ryzneuta for patients undergoing chemotherapy.
As part of the Delhi NCR region, the city has a strong concentration of cancer centers, making it a key location for accessing chemotherapy supportive-care medicines.
With a growing network of multispecialty and oncology hospitals, Bangalore supports access to Ryzneuta through structured import pathways guided by treating oncologists.
Home to several reputed cancer treatment centers, Chennai facilitates access to Ryzneuta for patients on myelosuppressive chemotherapy.
A growing hub for oncology care, Hyderabad supports coordinated access to Ryzneuta for eligible patients under specialist supervision.
Eastern India's leading cancer centers in Kolkata coordinate Ryzneuta access for patients undergoing chemotherapy.
With an expanding base of oncology clinics, Pune facilitates timely access to Ryzneuta under prescription.
Gujarat's leading cancer hospitals support regulated access to Ryzneuta for eligible patients.
Kerala's healthcare network, including major cancer centers in Kochi, coordinates access to supportive-care biologics like Ryzneuta.
Serving North India, Chandigarh's oncology centers facilitate access to Ryzneuta for patients from Punjab, Haryana, and Himachal Pradesh.
Rajasthan's leading hospitals support patient access to Ryzneuta through the Named Patient Program.
A key referral center for North India, Lucknow facilitates coordinated access to Ryzneuta under oncologist care.
Odisha's growing oncology sector supports patient access to Ryzneuta.
As a referral hub for the North-East, Guwahati facilitates access to Ryzneuta for patients across the region.
Access can also be coordinated for patients in other major Indian cities, subject to a valid prescription and regulatory requirements.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 08 September 2026
Sources: FDA • EMA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 08 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
